Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Rosas (REMDACTA)
 
NCT04409262
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
434/215 inconclusive
  • inconclusive 3 % decrease in hospital discharge (PE) with a moderate degree of certainty due to some concern in risk of bias
COVACTA (Rosas)
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
301/151 suggested
  • inconclusive 19 % increase in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).